Sheridan Capital Backs Tres Health in Alternative Insurance Push

Sheridan Capital Partners has completed a growth investment in Tres Health, a national alternative health insurance technology company, betting that small businesses will increasingly abandon traditional group coverage in favor of health sharing arrangements as premium costs continue climbing. The deal marks Sheridan's latest healthcare services play in a sector where cost inflation is outpacing wage growth by double digits.

The investment — financial terms weren't disclosed — comes as employer health insurance premiums hit record highs in 2026, with the average annual cost for family coverage now exceeding $25,000 according to the Kaiser Family Foundation. That's created an opening for alternative models like health sharing plans, which operate outside traditional insurance regulation and can cost 30-50% less than comparable ACA-compliant coverage.

Tres Health's platform connects employers and individuals with health sharing ministries — cooperative arrangements where members contribute monthly amounts that are pooled to cover medical expenses. The company's technology layer automates enrollment, claims processing, and member support for these plans, which have historically relied on paper-based administration. Founded in 2019, Tres Health claims to serve over 15,000 members across 48 states through partnerships with multiple health sharing organizations.

What makes this deal interesting isn't just the alternative insurance angle — it's the timing. Health sharing ministries have faced regulatory scrutiny in multiple states, with critics arguing they lack the consumer protections of traditional insurance. Several high-profile plan failures left members with unpaid medical bills in recent years. Sheridan is effectively betting that Tres Health's technology and vetting process can bring credibility to a sector that's been plagued by reputation issues.

The economics are straightforward. A small business with 20 employees paying $24,000 per year per family on traditional group insurance is looking at nearly $500,000 in annual healthcare costs if most workers have dependents. Switch to a health sharing plan at $600/month per family, and that same employer cuts costs to roughly $290,000 — a savings that can determine whether the company stays competitive or cuts headcount.

Those savings come with tradeoffs. Health sharing plans aren't insurance — they're exempt from the Affordable Care Act's coverage mandates, which means they can exclude pre-existing conditions, limit benefits for certain treatments, and deny claims more freely than regulated insurers. They also lack state guarantee funds that protect policyholders if an insurer fails.

But for businesses with relatively young, healthy workforces — think tech startups, construction firms, or service companies with high employee turnover — the risk calculation increasingly favors the cheaper option. And that's where Tres Health positions itself: not as a replacement for traditional insurance across the board, but as a viable alternative for specific employer segments where the coverage gaps matter less than the cost savings.

The company's pitch is that its technology makes health sharing plans function more like real insurance — automated claims, digital ID cards, provider network search tools, telemedicine integration. It's essentially applying the software-as-a-service model to an industry segment that's been stuck in the 1990s from an operational standpoint.

Sheridan Capital Partners, a Cleveland-based private equity firm with roughly $800 million in assets under management, focuses on lower mid-market companies generating $10-75 million in revenue. The firm has carved out a niche in healthcare services and technology-enabled business services — sectors where operational improvements and buy-and-build strategies can generate returns without requiring massive revenue growth.

Recent healthcare investments include behavioral health provider networks, home health agencies, and specialty pharmacy services. The Tres Health deal fits the pattern: a fragmented market with regulatory complexity, technology lagging behind consumer expectations, and unit economics that improve dramatically with scale.

What's less typical is the regulatory risk. Health sharing ministries exist in a legal gray zone — technically not insurance, but functionally similar enough that state regulators have started paying attention. Washington state banned new enrollments in 2023. Colorado imposed new disclosure requirements. Several other states are considering legislation that would subject health sharing plans to insurance-like oversight.

That regulatory uncertainty is presumably baked into Sheridan's investment thesis. Either the firm believes Tres Health's model is defensible under increased scrutiny, or the returns are attractive enough that even a partial exit before potential regulation tightens would generate acceptable returns. Neither scenario suggests this is a long-term hold in the traditional private equity sense.

Tres Health's core value proposition is software — specifically, software that makes non-insurance products behave like insurance from the user's perspective. That's not a trivial technical challenge, but it's also not an obvious moat. Enrollment platforms, claims processing systems, and member portals are well-understood technology categories. The barriers to entry aren't code — they're distribution relationships with health sharing ministries and trust with employer customers.

The health sharing market remains tiny relative to traditional insurance — roughly 1.5 million Americans are enrolled in health sharing plans as of 2025, compared to 160 million with employer-sponsored insurance and 50 million on ACA marketplace plans. But growth has been sharp: enrollment has tripled since 2020, driven primarily by small business adoption and self-employed individuals priced out of ACA plans.

Industry analysts project the alternative health coverage market could reach 5-7 million members by 2030 if premium inflation continues at current rates and regulatory crackdowns remain limited to a handful of states. That would represent a compounded annual growth rate of roughly 30%, making it one of the faster-growing segments of the broader healthcare economy.

But here's the catch: growth depends almost entirely on macro factors outside any individual company's control. If Congress expands ACA subsidies to cover more middle-income households, demand for alternative plans craters. If a major health sharing ministry collapses and leaves thousands of members with unpaid claims, regulatory backlash could freeze the market overnight. This isn't a sector where product innovation or superior execution insulates you from existential risk.

Tres Health's specific growth has reportedly outpaced the market — the company claims member count has grown 200% over the past 18 months — but from a small base. The 15,000-member figure puts the company's revenue somewhere in the $5-10 million range if they're capturing 5-10% of member contributions as platform fees, which is standard for the category. That's squarely in Sheridan's target range, but it also means the company needs to 5x or 10x to reach meaningful scale.

The path to that scale likely involves two simultaneous tracks: organic growth through employer channel expansion and inorganic growth through rolling up smaller competing platforms or acquiring distribution partnerships with additional health sharing organizations. The latter is the more certain path, which is presumably where Sheridan's operational resources will concentrate.

Tres Health isn't the only player attempting to modernize health sharing administration. Sedera, Solidarity HealthShare, and OneShare Health all operate technology platforms serving similar markets, though with varying levels of sophistication. Several traditional benefits administration companies — including Lumity and Zenefits — have begun adding health sharing options to their product catalogs as ancillary offerings.

What's notable is that none of the major healthtech venture firms have touched this sector. No Andreessen Horowitz, no General Catalyst, no Oak HC/FT. The regulatory risk and reputational concerns have kept institutional capital mostly on the sidelines, which creates opportunity for lower mid-market PE firms willing to operate in less popular categories. It also means exit options are constrained — this isn't a business that IPOs or gets acquired by UnitedHealth Group.

Step back from the specific companies, and the Sheridan-Tres Health deal is a bet on a darker thesis: that healthcare costs in the United States have spiraled so far out of control that businesses and individuals will accept materially worse coverage in exchange for affordability. That's not a feel-good narrative, but it's increasingly the reality for employers who can't absorb 8-12% annual premium increases indefinitely.

Health sharing plans don't solve the underlying cost problem — they just shift risk from insurers and employers onto individual members. When someone with an undiagnosed chronic condition joins a health sharing plan and discovers their treatment isn't covered, that cost doesn't disappear. It becomes medical debt, which often means unpaid providers, collection agencies, and eventually bankruptcy.

The growth of this market is less a story about innovation and more a symptom of system failure. Which raises an uncomfortable question for private equity investors: how long can you generate returns from a business model that exists primarily because the mainstream alternative has become unaffordable?

That's not a rhetorical question. If federal policy shifts toward Medicare-for-All or a robust public option, the alternative health coverage market contracts sharply or disappears entirely. If it doesn't — if the current trajectory continues — then Tres Health and its competitors are positioned at the leading edge of a genuine structural shift in how Americans access healthcare.

The press release mentions that Sheridan will support Tres Health's "continued growth and market expansion," which is the private equity equivalent of saying nothing. More specifically, the company will need to execute on several fronts simultaneously to justify the investment and position for exit.

First, geographic expansion. Currently operating in 48 states means there are regulatory gaps or operational constraints in a couple of markets — likely the ones with stricter oversight. Filling those gaps matters less than deepening penetration in existing markets, particularly in states with high small business density and limited ACA subsidy availability.

Second, channel partnerships. The employer benefits broker network is the distribution engine for anything sold to small businesses. Tres Health needs to become the default alternative coverage option that brokers recommend when traditional insurance pricing becomes prohibitive. That requires broker education, streamlined commission structures, and enough operational reliability that brokers don't get customer service blowback.

Third, the buy-and-build strategy. There are dozens of small health sharing platforms and administration companies operating regionally or in niche segments. Rolling up 3-5 of those over the next two years would rapidly expand member base, add distribution relationships, and position Tres Health as the clear category leader. That's textbook lower mid-market PE, and it's where Sheridan's operational expertise actually matters.

Sheridan typically holds investments for 4-7 years, which means an exit window starting around 2030. By then, the regulatory environment will either have stabilized in favor of health sharing plans — giving buyers confidence in the business model — or tightened significantly, which would compress valuations or eliminate strategic buyers entirely.

The most likely exit path is a sale to another private equity firm or a strategic buyer in the benefits administration space. Companies like Benefitfocus, bswift, or League could view Tres Health as a way to add alternative coverage products to their platforms. Health sharing ministries themselves might acquire the technology to bring administration in-house. But none of those are exits that generate venture-style multiples.

Valuation comps are tricky. Traditional insurance technology companies trade at 3-6x revenue depending on growth rates and margin profiles. Health sharing platforms likely command a discount due to regulatory risk and market size constraints — call it 2-4x revenue for a well-run operation. If Tres Health reaches $25-30 million in revenue by 2029 and maintains decent margins, an exit valuation in the $60-100 million range wouldn't be unreasonable.

That math works for a lower mid-market PE fund if the entry valuation was conservative and the company can grow at 40-50% annually with reasonable capital efficiency. It doesn't work if growth stalls at 20% or if a regulatory event forces a distressed sale. Which means the real performance metric to watch isn't quarterly revenue — it's member retention and the composition of the member base. Are people staying in these plans, or churning back to traditional insurance when they can afford it?

The most important variable in Tres Health's trajectory isn't anything the company controls — it's whether healthcare premium inflation continues accelerating. If 2027-2028 bring another round of 10%+ annual increases, alternative coverage adoption accelerates and Tres Health rides the wave. If inflation moderates or subsidy expansions make ACA plans more accessible, the market opportunity shrinks.

On the regulatory front, watch for state-level action in Texas, Florida, and Pennsylvania — the three largest markets for health sharing plans. If any of those states impose insurance-like requirements or restrict new enrollments, it changes the growth calculus significantly. Federal action is less likely in the near term, but CMS could tighten the definition of what qualifies as a health sharing ministry under ACA exemptions.

Finally, watch for competitor M&A. If a larger benefits platform acquires one of Tres Health's direct competitors, it validates the sector and potentially creates urgency for Sheridan to either accelerate the buy-and-build strategy or position for an earlier exit. Consolidation is coming in this space — the only question is who drives it and how quickly.

For now, Sheridan has placed a bet that small businesses are desperate enough to take risks on coverage that regulators don't fully trust. That's either a savvy read of a market in crisis, or a reminder that private equity returns sometimes depend on problems getting worse before they get better.